Received Jun 2, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (NO BRAND NAME) | UNKNOWN MANUFACTURER | UNK | — | — |
Suspected vaccination failure; Shingles; This serious case was reported by a consumer via call center representative and described the occurrence of vaccination failure in a female patient who received mepolizumab (Nucala) for product used for unknown indication. Co-suspect products included Herpes zoster (Shingles vaccine) solution for injection for prophylaxis. On an unknown date, the patient started Nucala and Shingles vaccine. On an unknown date, an unknown time after starting Nucala and an unknown time after receiving Shingles vaccine, the patient experienced vaccination failure (Verbatim: Suspected vaccination failure) (serious criteria GSK medically significant) and shingles (Verbatim: Shingles). The action taken with Nucala was unknown. The outcome of the vaccination failure was not reported and the outcome of the shingles was unknown. It was unknown if the reporter considered the vaccination failure and shingles to be related to Nucala and Shingles vaccine. The company considered the vaccination failure to be unrelated to Nucala and Shingles vaccine. GSK receipt date: 15-MAY-2026 The patient reports she received one dose of Nucala about 28 days ago and got Shingles. Patient reported that the Nucala undermined the Shingles vaccine she received. Her doctor had advised she no longer take Nucala. The patient received Mepolizumab as Nucala in the case. This case was considered as suspected vaccination failure as details regarding completion of primary vaccination schedule, time to onset and laboratory test confirming shingles were unknown at the time of reporting. The batch number was not provided upon follow up with the reporter.; Sender's Comments: A case of Vaccination failure, unknown time after starting Nucala and an unknown time after receiving Shingles vaccine, in a female patient. Based on the available information a possible causality that the event was caused by the GSK product cannot be ascertained. Consent for further follow-up has not been received.
Nucala